Review of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 30, Issue 4, 2013, Pages 249-261

  Xaubet, A ^a,b   Behr, J ^c   Bendstrup, E ^d   Cottin, V ^e   Hirani, N ^f   Kahler C M ^g   Skold C M ^h  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITÉ LYON 1   (France)

^f ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Diagnosis; Guidelines; IPF; Recommendations; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBROTIC AGENT;

ANTICOAGULANT THERAPY; CLINICAL PRACTICE; EUROPE; FIBROSING ALVEOLITIS; FUNCTIONAL STATUS; GERMANY; HUMAN; LUNG TRANSPLANTATION; MEDICAL SOCIETY; OXYGEN THERAPY; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY CONTROL; REVIEW; TREATMENT OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; IDIOPATHIC PULMONARY FIBROSIS;

EUROPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84901799456     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21(126): 355-61.
2. Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med 2012; 1: 479-87.
3. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157(4 Pt 1): 1301-15.
4. Raghu G, Collard HR, Egan JJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines For Diagnosis and Management. Am J Respir Crit Care Med 2011; 183: 788-824.
5. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-40.
6. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3: 8.
7. Vancheri C, Failla M, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
8. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22(129): 265-72.
9. Cottin V. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 2013; 14(Suppl 1): S5.
10. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-64.
11. Nadrous HF, Myers JL, Decker PA, Ryu JH. Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 2005; 80: 37-40.
12. Sakamoto K, Taniguchi H, Kondoh Y, Ono K, Hasegawa Y, Kitaichi M. Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease. Eur Respir Rev 2009; 18: 129-32.
13. Cottin V, Cordier JF.Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012; 40: 519-21.
14. Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22: 158-62.
15. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42: 750-7.
16. Cottin V, Wells A. Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category? Eur Respir J 2013; 42: 576-9.
17. Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013; 266: 936-44.
18. Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1043-7.
19. Schünemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 605-14.
20. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; (3): CD002880.
21. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; (3): CD003134.
22. Demedts M, Behr J, Buhl R, et al; IFIGENIA Study Group. Highdose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-42.
23. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-82.
24. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011; 20: 85-97.
25. Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.
26. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9.
27. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-7.
28. Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, Richeldi L. Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med 2012; 7: 42.
29. Orens J, Estenne M, Arcasoy S, et al. International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update-A consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant 2006; 25: 745-55.
30. Raghu G, Anstrom JA, King TE Jr., Lasky JA, Martinez FJ. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med 2012; 366: 1968-77.
31. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
32. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-9.
33. Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Eur Respir J 2013; May 16 (Epub ahead of print).
34. Daniels CE, Lasky JA, Limper AH, et al; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-10.
35. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-87.
36. Spagnolo P, Del Giovane C, Luppi F, et al.Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; (9): CD003134.
37. Costabel U, Albera C, Cohen A, The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study. Eur Respir J 2012; 40 (Suppl 56): 511s.
38. Behr J, Günther A, AmmenwerthW, et al. German guideline for diagnosis and management of idiopathic pulmonary fibrosis. Pneumologie 2013; 67: 81-111.
39. Behr J. Evidence-based treatment strategies in idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22: 163-8.
40. Xaubet A, Ancochea J, Bollo E, et al.Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol 2013; 49: 343-53.
41. Danish Society of Respiratory Medicine. http://www.lunge medicin.dk/side13.html. Accessed 11 August 2013.
42. Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis http://www.irishthoracicsociety. com/images/uploads/ITS%20Statement%20Final pdf. Accessed 11 August 2013.
43. Swedish Respiratory Society. Available at: http://www.slmf.se/v% C3%A5rdprogram. Accessed 25 September 2013.
44. Austrian Society of Pneumology. Available at: https: //www.google.it/search?q=Idiopathische+Lungenfibrose+(IPF)%3A+Diagnose+und+Therapie&oq=Idiopathische+Lungenfibrose+(IPF)%3A+Diagnose+und+Therapie&aqs=chrome.69i57.944j0&sourceid=chrome&espv=210&es-sm=93&ie=UTF-8. Accessed 11 August 2013.
45. British Thoracic Society. Interstitial lung disease guideline. Available at: http://www.brit-thoracic.org.uk/Guidelines/Interstitial-Lung-Disease-DPLD-Guideline.aspx. Accessed September 2013.
46. NICE. http://guidance.nice.org.uk/TA/WAVE23/25/FAD/Final-AppraisalDetermination/pdf/English. Accessed 11 August 2003.
47. Cottin V, Crestani B, Valeyre, et al. Recommandations pratiques pourle diagnostic et la prise en charge de la fibrose pulmonaire idiopathique Societe de Pneumologie de Langue Francaise. Rev Mal Respir 2013, http://dx.doi.org/10.1016/j.rmr.2013.09.007
48. Flaherty KR, Andrei A, King TE Jr, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007; 175: 1054-60.
49. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Practical Assessment, Research & Evaluation 2007; 12: 1-8.